Long-term survival and T-Cell kinetics in adult @entity1 with relapsed/refractory B-precursor XXXX who achieved @entity41 response following treatment with Anti-CD19 BiTE   antibody construct blinatumomab.

@entity1 @entity981 @entity4557 @entity41 @entity16877 @entity236 @entity6192 @entity1349
UNASSIGNED: This long-term follow-up analysis evaluated @entity1349 ( @entity1349 ) and @entity4557 ( @entity4557 ) in a phase 2 study of the bispecific T-cell engager (BiTE  ) antibody construct blinatumomab in 36 adults with relapsed/refractory B-precursor @entity981 . In the primary analysis, 25 (69%) @entity1 achieved complete remission with full (CR) or partial ( @entity6192 ) recovery of peripheral blood counts within the first 2 cycles. Twenty-five @entity1 (69%) had a @entity41 ( @entity41 ) response (< 10(-4) blasts), including 22 CR/ @entity6192 responders, two @entity1 with @entity236 , and one @entity1 with normocellular marrow but low peripheral counts. Ten of the 36 @entity1 (28%) were long-term survivors ( @entity1349 >=  30 months). Median @entity1349 was 13.0 months (median follow-up, 32.6 months). @entity41 response was associated with significantly longer @entity1349 (Mantel-Byar P = 0.009). All 10 long-term survivors had an @entity41 response. Median @entity4557 was 8.8 months (median follow-up, 28.9 months). A plateau for @entity4557 was reached after approximately 18 months. Six of the 10 long-term survivors remained relapse-free, including four who received allogeneic stem cell transplantation (alloSCT) as consolidation for blinatumomab and two who received three additional cycles of blinatumomab instead of alloSCT. Three long-term survivors had neurologic events or @entity16877 resulting in temporary blinatumomab discontinuation; all restarted blinatumomab successfully. Long-term survivors had more pronounced T-cell expansion than @entity1 with @entity1349 < 30 months.
